Date | Title | Description | Source |
05.03.2024 | Elafibranor for Primary biliary cholangitis (PBC) in 7MM: Ma... | - | globenewsw... |
26.09.2023 | Intercept, once a biotech trailblazer, sells itself for less... | Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hot... | statnews.c... |
23.06.2023 | Intercept Announces Restructuring to Strengthen Focus on Rar... | Measures reinforce Company’s ability to drive growth in PBC business and continue developing innovat... | einpresswi... |
28.04.2023 | Current NASH treatment hurdles highlighted, new drugs hailed... | Michael Betel, President and Founder of the Fatty Liver Alliance testifies at ICER.
Fatty Liver Alli... | einpresswi... |
11.11.2022 | Komodo Health & Intercept Partner to Study Rare Liver Di... | What You Should Know:
Intercept initially developed a traditional prospective trial to evaluate pati... | hitconsult... |
09.11.2022 | TES Pharma Congratulates Intercept Pharmaceuticals on their ... | INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept ... | en.prnasia... |
05.05.2022 | Sequoia, Andreessen Horowitz, a Saudi prince, and other inve... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
04.11.2021 | Corporate Presentation – November 2021 | Intercept
Pharmaceuticals
November 2021
Debbie,
Living with PBC
Cautionary Note Regarding Forward-Lo... | marketscre... |
03.11.2021 | Q3 2021 Earnings Call Presentation | Intercept Pharmaceuticals
2021 Third Quarter Financial and Corporate Update
November 3, 2021
Caution... | marketscre... |
03.11.2021 | Intercept Pharmaceuticals Reports Third Quarter 2021 Financi... | Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
... | marketscre... |
14.09.2021 | Intercept Pharmaceuticals : Baird 2021 Global Healthcare Con... | Intercept Pharmaceuticals
Baird 2021 Global Healthcare Conference
Jerry Durso, CEO
Cautionary Note R... | marketscre... |
29.07.2021 | Intercept Pharmaceuticals : Q2 2021 Earnings Call Presentati... | Intercept Pharmaceuticals
2021 Second Quarter Financial and Corporate Update
July 29, 2021
Cautionar... | marketscre... |
17.06.2021 | INTERCEPT PHARMACEUTICALS, INC.
Intercept Pharmaceuticals :... | Intercept
Pharmaceuticals
June 2021
Debbie,
Living with PBC
Cautionary Note Regarding Forward-Lookin... | marketscre... |
17.06.2021 | Intercept Pharmaceuticals : Corporate Presentation – June 20... | Intercept
Pharmaceuticals
June 2021
Debbie,
Living with PBC
Cautionary Note Regarding Forward-Lookin... | marketscre... |
05.06.2021 | Intercept Pharmaceuticals : Company narrows 2021 financial g... | Company narrows2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 mil... | marketscre... |
12.05.2021 | Intercept Pharmaceuticals : Corporate Presentation – May 202... | Intercept
Pharmaceuticals
May 2021
Debbie,
Living with PBC
Cautionary Note Regarding Forward-Looking... | marketscre... |
12.05.2021 | INTERCEPT PHARMACEUTICALS, INC.
Intercept Pharmaceuticals :... | Intercept
Pharmaceuticals
May 2021
Debbie,
Living with PBC
Cautionary Note Regarding Forward-Looking... | marketscre... |
06.05.2021 | INTERCEPT PHARMACEUTICALS, INC.
Intercept Pharmaceuticals :... | Company narrows2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 mil... | marketscre... |
05.04.2021 | Intercept Pharmaceuticals : Company Capability Presentation | Intercept
Pharmaceuticals
March 2021
Debbie,
Living with PBC
Cautionary Note Regarding Forward-Looki... | marketscre... |
05.04.2021 | INTERCEPT PHARMACEUTICALS, INC.
Intercept Pharmaceuticals :... | Intercept
Pharmaceuticals
March 2021
Debbie,
Living with PBC
Cautionary Note Regarding Forward-Looki... | marketscre... |
10.03.2021 | Grifols snags the rest of GigaGen in $80M acquisition;... | Spain’s Grifols is putting up $80 million to buy out the 56% of equity in GigaGen it doesn’t a... | endpts.com... |
10.03.2021 | Arctic Vision collects $100M to bring US eye disease can... | With three eye disease candidates, in-licensed from the US, Shanghai-based Arctic Vision has ... | endpts.com... |
10.03.2021 | Covid-19 roundup: US lands another 100M-dose contract fro... | With headlines around the globe focused on various hitches in the global supply chain for Cov... | endpts.com... |
10.03.2021 | AgomAb Therapeutics looks to take its 'true MET agonist... | Years ago, argenx reached out to Paolo Michieli, an Italian professor at the University of T... | endpts.com... |
10.03.2021 | Innovation in the clinic is picking up steam. How adap... | Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in bi... | endpts.com... |
10.03.2021 | Thermo Fisher will drop a whopping $600M into its manu... | Intercept’s leadership has now been almost entirely hollowed out and turned over. On Wednesday, the ... | endpts.com... |
10.03.2021 | FDA calls out Kardashian drug promo video for false claim... | The FDA is clearly keeping up with the Kardashians as its Office of Prescription Drug Promo... | endpts.com... |
10.03.2021 | Thermo Fisher will drop a whopping $600M into its manu... | Gene therapy player bluebird bio ran into a big stumbling block last month when they voluntarily pla... | endpts.com... |
10.03.2021 | Another SPAC is gearing up to go public, this time comi... | Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmar... | endpts.com... |
10.03.2021 | Thermo Fisher will drop a whopping $600M into its manu... | A US House of Representatives subcommittee on Tuesday reignited bipartisan angst around the FDA’s dr... | endpts.com... |
25.02.2021 | INTERCEPT PHARMACEUTICALS, INC.
Intercept Pharmaceuticals :... | Intercept Pharmaceuticals
Q4 and Full Year 2020 Earnings Call Presentation
February 25, 2021
Caution... | marketscre... |
25.02.2021 | Intercept Pharmaceuticals : Q4 2020 Earnings Call Presentati... | Intercept Pharmaceuticals
Q4 and Full Year 2020 Earnings Call Presentation
February 25, 2021
Caution... | marketscre... |
09.11.2020 | INTERCEPT PHARMACEUTICALS, INC.
Intercept Pharmaceuticals :... | Intercept
Pharmaceuticals
Q3 2020 Earnings Call Presentation
November 9, 2020
Cautionary Note Regard... | marketscre... |
09.11.2020 | INTERCEPT PHARMACEUTICALS, INC.
Intercept Pharmaceuticals :... | Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over... | marketscre... |
11.09.2020 | Intercept Pharmaceuticals : Reports Third Quarter 2020 Finan... | Worldwide Ocaliva net sales of $79.5 million in the third quarter 2020, representing 29% growth over... | marketscre... |
11.09.2020 | Intercept Pharmaceuticals : Q3 2020 Earnings Call Presentati... | Intercept
Pharmaceuticals
Q3 2020 Earnings Call Presentation
November 9, 2020
Cautionary Note Regard... | marketscre... |
10.08.2020 | INTERCEPT PHARMACEUTICALS, INC.
Intercept Pharmaceuticals :... | Intercept
Pharmaceuticals
Q2 2020 Earnings Call Presentation
August 10, 2020
Cautionary Note Regardi... | marketscre... |
29.06.2020 | FDA turns down Intercept’s long-anticipated NASH drug | Shares of Intercept were down 39.5% on the Nasdaq in midday trading following the news.
Expressing d... | medcitynew... |
29.06.2020 | INTERCEPT PHARMACEUTICALS, INC.
Intercept Receives Complete... | NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biophar... | marketscre... |
26.03.2020 | Biopharma companies face regulatory, deal delays due to Covi... | Meanwhile, Cambridge, Massachusetts-based bluebird bio said did not anticipate completing its rollin... | medcitynew... |
17.12.2019 | Intercept hits slight delay in NASH drug approval, but analy... | Indeed, the announcement did not appear to affect Intercept’s stock price, with shares rising 5% on ... | medcitynew... |
13.12.2019 | More questions than answers for biopharma after UK elec... | → On Thursday, voters in the UK handed Boris Johnson’s Conservative government, and its ag... | endpts.com... |
26.11.2019 | Genfit scores seventh positive data safety monitoring board ... | Shares of Genfit were up 8.3% on the Euronext Paris exchange and 3.5% on the Nasdaq following the ne... | medcitynew... |
11.11.2019 | 89Bio goes public and the stock price surges | 89Bio company is developing a drug called BIO89-100 that is in Phase I/Phase 2b development for nona... | medcitynew... |
11.04.2019 | Intercept’s Ocaliva shows continued improvement in NASH fibr... | Shares of Intercept were down more than 13 percent on the Nasdaq Thursday afternoon.
The data showed... | medcitynew... |
27.03.2019 | France's NASH contender Genfit leaps onto Nasdaq with $1... | As it gears up for the late-stage readout of its lead experimental NASH drug, France’s Genfit ... | endpts.com... |
19.02.2019 | Intercept could score first NASH drug approval on positive P... | Shares of Intercept opened up 18.6 percent on the Nasdaq Tuesday following the news.
The results com... | medcitynew... |
07.12.2017 | Rich Heyman's Metacrine grabs a $22M round in search of a s... | A startup founded by biotech A-listers has scored $22 million in a Series B round to help deve... | endpts.com... |
04.05.2017 | Novartis continues its blitz on NASH deals, grabbing an... | Vasant Narasimhan, Novartis
Five months ago Novartis $NVS rocked Conatus’ world with a collab... | endpts.com... |
10.08.2012 | Intercept Pharmaceuticals Completes $30M Series C Financing | Intercept Pharmaceuticals, Inc., a NYC-based clinical stage biopharmaceutical company focused on the... | finsmes.co... |
25.01.2010 | Intercept Pharmaceuticals Raises $25M Series B Financing | Intercept Pharmaceuticals, Inc., a New York-based clinical stage biopharmaceutical company developin... | finsmes.co... |
- | Intercept’s Ocaliva shows continued improvement in NASH fibr... | A company that could become the first to win Food and Drug Administration approval for a drug to tre... | medcitynew... |
- | Biopharma companies face regulatory, deal delays due to Covi... | Covid-19 is already taking a toll on biopharma, with companies putting off clinical development and ... | medcitynew... |
- | FDA turns down Intercept’s long-anticipated NASH drug | A drug that had been expected to become the first to win regulatory approval for the fatty liver dis... | medcitynew... |
- | Genfit scores seventh positive data safety monitoring board ... | The committee overseeing Genfit’s registration-directed Phase III trial testing its drug in a fatty-... | medcitynew... |
- | Intercept hits slight delay in NASH drug approval, but analy... | A company that could become the first to win Food and Drug Administration approval for a drug to tre... | medcitynew... |
- | 89Bio goes public and the stock price surges | A year after announcing that it received a $60 million Series A funding, San Francisco-based 89Bio w... | medcitynew... |
- | Intercept could score first NASH drug approval on positive P... | A drug in development for nonalcoholic steatohepatitis took a step closer to regulatory approval Tue... | medcitynew... |